Guangxi Key Laboratory of Reproductive Health and Birth Defect Prevention, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530003, China; Guangxi Key Laboratory of Precision Medicine for Genetic Diseases, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530003, China; Guangxi Key Laboratory of Birth Defects Research and Prevention, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530003, China; Guangxi Key Laboratory of Birth Defects and Stem Cell Biobank, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530003, China; Genetic and Metabolic Central Laboratory, Birth Defects Prevention and Control Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530003, China; Guangxi Clinical Research Center for Pediatric Diseases, China.
Genetic and Metabolic Central Laboratory, Birth Defects Prevention and Control Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530003, China.
Clin Chim Acta. 2022 Feb 1;526:74-80. doi: 10.1016/j.cca.2021.12.025. Epub 2022 Jan 3.
The mitochondrial translation optimization factor 1(MTO1) gene mutations had been reported to be linked to combined oxidative phosphorylation defificiency-10 (COXPD10). In this study, we presented the detailed clinical features and genetic analysis of the patient with two variants in MTO1, and reviewed 42 different cases available in publications. Whole exome sequencing and bioinformatics analysis were employed to detect the genetic variants of a 6-month-old boy with metabolic disorder and multiple organ failure; Sanger sequencing was performed to confirm the origin of variants; and clinical data of the patients was retrospectively collected and analyzed. Variant classification was followed to ACMG guidline. The proband was diagnosed with multiple organ failure, severe pneumonia, sepsis, hyperlactatemia, metabolic acidosis, and moderate anemia. Compound heterozygous mutations in the coding region of MTO1 gene (c.1291C > T/p.Arg431Trp and c.1390C > T/p.Arg464Cys) were identified, and the results of family verification experiment showed that the mutations were inherited from the parents, respectively. Combined with clinical symptoms, the patient was diagnosed as COXPD10. In summary, hallmark features of MTO1 mutations were lactic acidosis and hypertrophic cardiomyopathy. Of note, patients with the same genetic mutation may not have the same clinical presentation. Additional MTO1 defificiency cases will help to make genotype-phenotype correlations clearer.
线粒体翻译优化因子 1(MTO1)基因突变与联合氧化磷酸化缺陷 10 型(COXPD10)有关。本研究报道了一位 MTO1 两个变异的患者的详细临床特征和基因分析,并对已发表的 42 例不同病例进行了综述。我们采用外显子组测序和生物信息学分析来检测一位 6 月龄代谢障碍和多器官衰竭患儿的遗传变异;采用 Sanger 测序来确认变异的来源;并回顾性收集和分析患者的临床数据。根据 ACMG 指南对变异进行分类。先证者被诊断为多器官衰竭、严重肺炎、脓毒症、高乳酸血症、代谢性酸中毒和中度贫血。在 MTO1 基因编码区发现了复合杂合突变(c.1291C>T/p.Arg431Trp 和 c.1390C>T/p.Arg464Cys),家系验证实验的结果表明这些突变分别来自父母。结合临床症状,该患者被诊断为 COXPD10。总之,MTO1 突变的特征性表现为乳酸酸中毒和肥厚型心肌病。值得注意的是,具有相同遗传突变的患者可能具有不同的临床表现。更多的 MTO1 缺乏症病例将有助于更清楚地阐明基因型-表型相关性。